Left ventricular hypertrophy (LVH) is an independent cardiovascular risk factor; however, the key strategy necessary for LVH regression in hypertensive patients is not clear. A meta-analysis was conducted to study the effect of blood pressure reduction on LVH regression. We explored the relationship between different degrees of systolic blood pressure (SBP)/diastolic blood pressure (DBP) reduction and LVH regression. A total of 17 randomized controlled trials comprising 2196 hypertensive patients (mean age, 56.3 years; 64.1% were men) were identified. L20 and DBP L10 groups (Po0.0001). The most significant decrease in LVH was seen in patients with a mean age over 60 years in the DBP M10 group. Moreover, the renin-angiotensin system inhibitor was found to be the most effective antihypertensive drug for LVH regression. This meta-analysis result indicates that proper DBP reduction plays an important role in the regression of echocardiographic LVH in hypertensive patients. 1 LVH, a strong predictor of cardiovascular morbidity and mortality, is associated with increased congestive heart failure, myocardial infarction, stroke and sudden death. [2] [3] [4] In essential hypertensive patients, patterns of LVH include increased LV mass and wall thickness, reduced LV volume (concentric hypertrophy); increased wall thickness, reduced LV volume, normal LV mass (concentric remodeling); and increased LV mass with volume (eccentric hypertrophy). All patterns of LVH often lead to decreased LV compliance and impaired LV systolic and diastolic function.
INTRODUCTION
Left ventricular hypertrophy (LVH) is well recognized as a common form of cardiac damage in hypertension. 1 LVH, a strong predictor of cardiovascular morbidity and mortality, is associated with increased congestive heart failure, myocardial infarction, stroke and sudden death. [2] [3] [4] In essential hypertensive patients, patterns of LVH include increased LV mass and wall thickness, reduced LV volume (concentric hypertrophy); increased wall thickness, reduced LV volume, normal LV mass (concentric remodeling); and increased LV mass with volume (eccentric hypertrophy). All patterns of LVH often lead to decreased LV compliance and impaired LV systolic and diastolic function.
The association of LVH with hypertension has been documented earlier. Blood pressure reduction was found to contribute to the regression of LVH.
1 Sustained blood pressure reduction caused continued decrease in the prevalence of LVH. 5 However, it is still unclear as to control of which pattern of blood pressure, systolic blood pressure (SBP) or diastolic blood pressure (DBP), is more beneficial for LVH regression.
Both SBP and DBP are important determinants of LVH in hypertensive patients. It is generally believed that SBP has greater association with LVH compared with DBP. 6, 7 However, the change in emphasis towards SBP has assumed importance only recently. Moreover, lowering SBP is not always beneficial for lowering cardiovascular risk. Recently, a study found that reducing SBP to 130 mm Hg or lower was not associated with lower cardiovascular risk compared with SBP of 131-141 mm Hg; instead, it was associated with a significantly increased risk of death and trend toward increased cardiovascular mortality. 8 However, the optimum level of SBP or DBP for LVH regression is still under debate.
The aim of this study was to determine which of the two, SBP reduction or DBP reduction, had a greater effect on echocardiographic LVH regression in hypertensive patients and determine the effect of different degrees of SBP/DBP reduction on LVH regression in hypertensive patients.
MATERIALS AND METHODS

Search strategy
papers should have been published in peer-reviewed journals; (3) the publication should have been written in English; (4) LVH should have been estimated by left ventricular mass index (LVMI), which was calculated as left ventricular mass (g) divided by body surface area (m 2 ); (5) study duration should have been for at least 6 months; (6) all patients should have been older than 18 years; (7) SBP, DBP and LVMI values had been reported at baseline and at the end of follow-up; (8) all patients should have had treated or never-treated essential, nonmalignant hypertension; and (9) the study should have a study quality score X4 (modified Jadad scale). The studies that normalized LVMI for height 2.7 were excluded. Left ventricular mass was measured by echocardiography. .
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Outcome measures
The primary outcome measure was the change in LVMI. The subgroup analysis was based on reductions in SBP and DBP, age and drug classifications.
Data extraction
Data were extracted independently by two investigators. Discrepancies were resolved by consensus. The following data were extracted from all included studies: study design, name of the authors, name of the journal, duration of the study, number of included patients, sex ratio, follow-up intervals, age, drug classifications, and SBP, DBP and LVMI levels at baseline and at the end of follow-up.
Subgroup definition
The JNC 7 report (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure) provided a key message that the risk of cardiovascular disease, beginning at 115/75 mm Hg, doubles with each increment of 20/10 mm Hg. 9 Thus, we grouped the studies based on the reduction degree of SBP or DBP (20/10 mm Hg). In the analysis of the relationship between SBP reduction and LVH regression, the group with the reduction of SBP X20 mm Hg was defined as the SBP M20 group, and that with the reduction of SBP o20 mm Hg was defined as the SBP L20 group. In the analysis of the relationship between DBP reduction and LVH regression, the group with the reduction of DBP X10 mm Hg was defined as the DBP M10 group and that with the reduction of DBP o10 mm Hg was defined as the DBP L10 group. Each RCT wascomposed of two or more treatment arms, and each type of treatment was taken as a separate observation.
Assessment of study quality Methodological quality was conducted using the modified Jadad scale. 10 An eight-item scale was designed to assess the included RCTs. Scores of 4-8 denoted high quality, and scores of 0-3 represented low quality. We analyzed only studies of high quality.
Statistical analysis
Statistical analyses were performed using Stata version 12.0 (Stata Corp, College Station, TX, USA). As for continuous outcomes, results were presented as weighted mean difference (WMD) and 95% confidence intervals (CIs). The statistical heterogeneity across studies was assessed using I 2 statistics, with significance being set at I 2 450%. We used fixed-or random-effects models in the absence or presence of heterogeneity between studies. Publication bias was evaluated using funnel plots, Begg test and Egger test. The unpaired t-test was used to make comparisons between groups. Finally, we used metaregression analysis to analyze the possible sources of heterogeneity. Statistical significance was defined at Po0.05.
RESULTS
Study selection
A total of 17 RCTs with 2196 hypertensive patients were identified for inclusion from 388 potentially relevant publications ( Figure 1 ).
Baseline characteristics and study quality The main baseline characteristics and study quality of the 17 studies that were included are summarized in Table 1 . A total of 2196 hypertensive patients with a mean age range of 50.4-65.8 years were identified, and of them 64.1% were men. The mean . In the identified studies, sample size ranged from 30 to 411 participants, mean follow-up interval was from 6 to 48 months and the study quality score ranged from 4 to 7. Five antihypertensive drug classifications were mainly used in the studies: angiotensinconverting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), b-receptor blockers (b-blockers), calcium channel blockers (CCB) and diuretics.
SBP reduction and regression of LVH LVH was estimated by LVMI. LVMI regression was significantly associated with reduction in blood pressure (WMD: 14.54 g m À 2 ; 95% CI: 11.52, 17.57; Po0.0001) (Figure 2 (Figure 3) . Comparison of the mean LVMI regression value showed a significant difference between the two SBP subgroups (t ¼ À 4.67, Po0.0001). Figure 4 showed that the regression of LVMI was significantly associated with DBP reduction (DBP M10 group -WMD: 15.17 g m ) when DBP decreased more than 10 mm Hg, regardless of the reduction of SBP over 20 mm Hg (Table 2) .
DBP reduction and regression of LVH
LVH regression in different age groups of DBP M10 We first grouped the studies of DBP M10 into two age groups: 60 years or older and 60 years or younger. Results showed that LVMI in the first group showed greater regression compared with the second group (17.50 vs 14.64 g m À 2 , Po0.0001; Figure 5 ). Thereafter, we compared the degree of DBP decrease between the two age groups; however, no significant difference was found (13.55 vs 13.84 mm Hg, t ¼ À 0.17, P ¼ 0.87).
Different antihypertensive drugs and the regression of LVH The studies were also divided into four categories on the basis of the types of antihypertensive drugs used: the renin-angiotensin Figure 3 . The relation between SBP reduction and LVH regression. CI, confidence interval; SBPM20, reduction 427 of SBP .X20 mmHg; SBPLo20, reduction of SBP o 20 mmHg; WMD, weighted mean 428 difference. system inhibitor (RASI) (ACEI/ARB) group, the b-blockers group, the CCB group, and diuretics and others group. Figure 6 showed that RASI led to greater decreases in LVH (17.85 g m À 2 ), followed by CCB (15.20 g m ) and diuretics and others (9.16 g m À 2 ). The comparison among groups showed significant differences (Po0.0001).
Determinants of statistical heterogeneity Potential variables analyzed in the univariate meta-regression analysis identified the sources of statistical heterogeneity among studies (Table 3 ). Both sample size and drug classifications contributed to the statistical heterogeneity (sample size, P ¼ 0.049; drug classifications, P ¼ 0.023; Table 3 ). However, factors like age, follow-up duration, blood pressure, LVMI at baseline and study quality showed no contributions ( Table 3 ). The multivariable weighted meta-regression analysis proved that the statistical heterogeneity can be definitely explained by the two variables (sample size, P ¼ 0.028; drug classifications, P ¼ 0.011).
Publication bias When we explored for potential publication bias, the funnel plot did not appear asymmetrical (Figure 7) , and both Begg and Egger tests were not significant (Begg test, P ¼ 0.55; Egger test, P ¼ 0.71).
DISCUSSION
This meta-analysis suggested that, in hypertensive patients, both SBP and DBP reductions were successful at decreasing LVH. The regression of LVH is most obvious when DBP decreased more than 10 mm Hg, especially in patients with a mean age over 60 years. Furthermore, RASI drugs were found to be the most effective antihypertensive drugs for decreasing LVH.
SBP and DBP are the two determinants for LVH. The strategy of controlling SBP or DBP has been under debate for many years. Emphasis on the importance of SBP has gradually intensified in recent times. 11, 12 Scientists stressed upon the importance of SBP mainly because: (1) SBP gradually increases with age, whereas DBP increases with age until around 50 years and thereafter falls; (2) systolic hypertension is a major pattern in elderly hypertensive 12 and (3) a lowered DBP can compromise coronary perfusion, and when DBP drops below 60 mm Hg it will increase the risk of cardiovascular events. 13 However, DBP should be combined with SBP for better blood pressure management.
14 In this meta-analysis, we found that lowering of DBP is more important than lowering of SBP for LVH regression, which is at variance with the results of a previous study. 7 Several potential mechanisms may explain this phenomenon. First, DBP is mostly influenced by peripheral resistance. Increased peripheral resistance subsequently leads to high DBP. It is known that peripheral resistance is often regulated by the sympathetic nervous system and the renin-angiotensin system. Both systems are often overactive in hypertensive patients. 15 It becomes clear that the disturbance to the sympathetic nervous system and renin-angiotensin system can influence the systolic and diastolic functions of the heart, which is a basic mechanism of LVH. 16 Second, in elderly patients the common manifestation of high SBP and low DBP is mostly due to stiffness of the large arteries due to vascular resistance. 17 However, it does not indicate whether high DBP 'burn out' and 'normal' DBP are truly safe for preventing cardiovascular events. In contrast, the pulse pressure increases, and this increase in pulse pressure in turn serves as a strong predictor of cardiovascular diseases. 18 Third, the patients included in our study generally had a mean DBP of 90 mm Hg or higher in conjunction with a mean SBP X140 mm Hg. In clinics, this stage is commonly called systolic-diastolic hypertension, which may have the same pathophysiologic process as isolated diastolic hypertension, 19 and the high DBP plays a dominant role in the clinical manifestation. In fact, blood pressure reduction is a double-edged sword because not only SBP but also DBP should be maintained at a reasonable level.
In our study, we also extended the research scope to younger patients to prove that DBP reduction had greater effect on LVH regression. Surprisingly, the results showed that LVH did not decrease more in younger patients (age o60 years) compared with older patients (age X60 years). The possible explanation may be that the older group had a relatively smaller sample size and the mean age did not exceed 65 years, which, therefore, could not represent the older population. However, the mean age of the younger age group was mostly over 50 years, and thus this group may have had similar characteristics with the older group, as the patients of the included studies all had a high SBP and DBP. In addition, the reduction in DBP showed no difference between the two age groups. It indicated that age was an independent factor influencing LVH regression, regardless of DBP reduction.
In clinical practice, we commonly treat blood pressure in hypertensive patients following the guidelines of the World Health Organization. The World Health Organization recommends that blood pressure control be kept below 140/90 mm Hg for essential hypertensive patients, and at a lower therapeutic goal of below 130/80 mm Hg for patients with diabetes and for those at increased cardiovascular risk for other reasons. 20, 21 However, a series of recent studies found that this guideline has failed to help patients gain the best benefits. For example, in patients with type 2 diabetes, achieving the target blood pressure levels did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events. 22 Further, in patients with cardiovascular disease, a low blood pressure even portends an increased risk of future cardiovascular events. 13 However, the optimum blood pressure goal for LVH regression is not clear. In our study, we found that LVH regressed significantly when DBP decreased over 10 mm Hg, regardless of the effects of SBP reducing over 20 mm Hg or achieving the target blood pressure level. In fact, the phenomenon of LVH regression depending less on achieving the target SBP was found earlier in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study.
It revealed that, although the target SBP was not achieved, the antihypertensive therapy still resulted in significant regression of electrocardiographic LVH. 23 However, we acknowledged that, although our study found a reduction of DBP more than 10 mm Hg Figure 6 . Different antihypertensive drugs and the regression of LVH. ACEI, angiotensin-converting enzyme inhibitors; ARB, 438 angiotensin receptor blockers; b-blockers, beta-receptor blockers; CCB, calcium 439 channel blockers; CI, confidence interval; WMD, weighted mean difference. as LVH regressed markedly, the degree of DBP reduction should be carefully considered because of the existence of the diastolic J curve. In our study, the fact that the DBP M10 group showed greater reduction in LVH compared with the DBP L10 group indicated that there may be a threshold of DBP for LVH regression below which patients would not derive benefits. When we explored the potential heterogeneity between studies, we found that sample size and drug classifications partially explained the statistical heterogeneity. However, other factors such as age, follow-up duration, blood pressure, LVMI at baseline and study quality showed no contributions. The difference in sample size is inevitable. In addition, drug classifications were found to be associated with the studies' objective. In our study, four major kinds of antihypertensive drugs used in each RCT have been included. Thefindings showed that all the major antihypertensive drugs could decrease LVH. RASI was more potent in reducing LVH compared with CCB, b-blockers and diuretics. Consequently, RASI should be recommended as the first-line antihypertensive drug to reverse LVH.
In conclusion, it is well known that the prognosis of hypertensive patients will be poor when accompanied by LVH. A series of factors are involved in the regression of LVH -for example, antihypertensive drugs and the strategy of decreasing blood pressure. This meta-analysis found that DBP reduction is important for LVH regression in hypertensive patients, especially for patients over 60 years. It indicates that, in hypertensive patients, if DBP reduction is not managed well, the LVH regression will not be satisfied and the prognosis may be poorer. Thus, decreasing DBP more than 10 mm Hg (above the J curve point or at the possible threshold) may be a good method for LVH regression and for reducing cardiovascular events in hypertensive patients.
Study limitation
It must be acknowledged that there are several limitations to this study. First, our extracted data were not the original data. Although we analyzed the studies by age and drug classifications, it was impossible to adjust factors such as heart rate, blood pressure at baseline and so on. Moreover, there were insufficient data on dietary salt intake and pulse wave for a reliable analysis in this study. Second, the patients' mean blood pressure was usually at World Health Organization stage 1 or 2, with the mean age range being 50.4-65.8 years. More studies are needed to determine whether LVH regression would be effective in severe hypertensive patients or in other age groups. In addition, the subgroups are grouped a little roughly, and the optimum goal of blood pressure reduction is still uncertain. Further, multicenter RCT studies are needed to detail the blood pressure stratification and estimate the optimum goal of blood pressure that promotes LVH regression.
What is known about the topic LVH is a strong predictor of cardiovascular morbidity and mortality. Lowering blood pressure using different antihypertensive drugs is associated with LVH regression. Both SBP and DBP are important determinants of LVH in hypertensive patients.
What this study adds
Proper DBP reduction plays an important role in the regression of echocardiographic LVH. DBP reduction was not found to be more important in younger patients (age o60 years) for LVH regression. RASI was the most effective antihypertensive drug for LVH regression.
